These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 29697934)

  • 1. 5-alpha Reductase Inhibitors and risk of male breast cancer: a systematic review and meta-analysis.
    Wang J; Zhao S; Luo L; Li E; Li X; Zhao Z
    Int Braz J Urol; 2018; 44(5):865-873. PubMed ID: 29697934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of 5α-Reductase Inhibitors on Sexual Function: A Meta-Analysis and Systematic Review of Randomized Controlled Trials.
    Liu L; Zhao S; Li F; Li E; Kang R; Luo L; Luo J; Wan S; Zhao Z
    J Sex Med; 2016 Sep; 13(9):1297-1310. PubMed ID: 27475241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between 5-Alpha Reductase Inhibitor Use and The Risk of Depression: A Meta-Analysis.
    Deng T; Duan X; He Z; Zhao Z; Zeng G
    Urol J; 2020 Aug; 18(2):144-150. PubMed ID: 32869255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Male breast cancer and 5α-reductase inhibitors finasteride and dutasteride.
    Bird ST; Brophy JM; Hartzema AG; Delaney JA; Etminan M
    J Urol; 2013 Nov; 190(5):1811-4. PubMed ID: 23665270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sexual, physical, and overall adverse effects in patients treated with 5α-reductase inhibitors: a systematic review and meta-analysis.
    Zhang JJ; Shi X; Wu T; Zhang MD; Tang J; Yin GM; Long Z; He LY; Qi L; Wang L
    Asian J Androl; 2022; 24(4):390-397. PubMed ID: 34747724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of Data From Breast Diseases Treated With 5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia.
    Fang Q; Chen P; Du N; Nandakumar KS
    Clin Breast Cancer; 2019 Oct; 19(5):e624-e636. PubMed ID: 31126837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Finasteride treatment and male breast cancer: a register-based cohort study in four Nordic countries.
    Meijer M; Thygesen LC; Green A; Emneus M; Brasso K; Iversen P; Pukkala E; Bolin K; Stavem K; Ersbøll AK
    Cancer Med; 2018 Jan; 7(1):254-260. PubMed ID: 29239131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selenium for preventing cancer.
    Vinceti M; Filippini T; Del Giovane C; Dennert G; Zwahlen M; Brinkman M; Zeegers MP; Horneber M; D'Amico R; Crespi CM
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD005195. PubMed ID: 29376219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis.
    Corona G; Tirabassi G; Santi D; Maseroli E; Gacci M; Dicuio M; Sforza A; Mannucci E; Maggi M
    Andrology; 2017 Jul; 5(4):671-678. PubMed ID: 28453908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of 5-alpha reductase inhibitors: new insights on benefits and harms.
    Lee JY; Cho KS
    Curr Opin Urol; 2018 May; 28(3):288-293. PubMed ID: 29528971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5α-Reductase inhibitors increase acute coronary syndrome risk in patients with benign prostate hyperplasia.
    Chou CH; Lin CL; Lin MC; Sung FC; Kao CH
    J Endocrinol Invest; 2015 Jul; 38(7):799-805. PubMed ID: 25778849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-α reductase inhibitors, benign prostatic hyperplasia, and risk of male breast cancer.
    Robinson D; Garmo H; Holmberg L; Stattin P
    Cancer Causes Control; 2015 Sep; 26(9):1289-97. PubMed ID: 26109464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term use of 5α-reductase inhibitors and the risk of male breast cancer.
    Duijnhoven RG; Straus SM; Souverein PC; de Boer A; Bosch JL; Hoes AW; De Bruin ML
    Cancer Causes Control; 2014 Nov; 25(11):1577-82. PubMed ID: 25135615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The association of α-blockers and 5-α reductase inhibitors in benign prostatic hyperplasia with fractures.
    Lim SY; Laengvejkal P; Panikkath R; Nugent K
    Am J Med Sci; 2014 Jun; 347(6):463-71. PubMed ID: 24270079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness of 5-alpha reductase inhibitors for the prevention of prostate cancer in multiple patient populations.
    Earnshaw SR; McDade CL; Black LK; Bell CF; Kattan MW
    Pharmacoeconomics; 2010; 28(6):489-505. PubMed ID: 20196623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of 5-Alpha-Reductase Inhibitors Use at the Time of Prostatic Artery Embolization for Treatment of Benign Prostatic Obstruction.
    Cardarelli-Leite L; de Assis AM; Moreira AM; Antunes AA; Cerri GG; Srougi M; Carnevale FC
    J Vasc Interv Radiol; 2019 Feb; 30(2):228-232. PubMed ID: 30717954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of gynecomastia and breast cancer associated with the use of 5-alpha reductase inhibitors for benign prostatic hyperplasia.
    Hagberg KW; Divan HA; Fang SC; Nickel JC; Jick SS
    Clin Epidemiol; 2017; 9():83-91. PubMed ID: 28228662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Model-based cost-effectiveness analyses for prostate cancer chemoprevention : a review and summary of challenges.
    Earnshaw SR; Brogan AP; McDade CL
    Pharmacoeconomics; 2013 Apr; 31(4):289-304. PubMed ID: 23519744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A population-based nested case-control study: the use of 5-alpha-reductase inhibitors and the increased risk of osteoporosis diagnosis in patients with benign prostate hyperplasia.
    Lin WL; Hsieh YW; Lin CL; Sung FC; Wu CH; Kao CH
    Clin Endocrinol (Oxf); 2015 Apr; 82(4):503-8. PubMed ID: 25158777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.